Hospital and medical care days in pancreatic cancer

Casey A. Boyd, Daniel W. Branch, Kristin M. Sheffield, Yimei Han, Yong Fang Kuo, James Goodwin, Taylor S. Riall

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Little is known about resource utilization (number of days in the hospital or medical care) between diagnosis and death in patients with pancreatic cancer. Methods: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified 25,476 patients with pancreatic cancer (1992-2005). Hospital and medical care days per person-month from the time of diagnosis were described, stratified by stage, treatment, and survival duration. Results: Hospital/medical care days vary by length of survival and treatment strategy in patients with pancreatic cancer. For all stages, patients were in the hospital a mean of 6.4 days and received medical care a total of 9.0 days in the first month after diagnosis, decreasing to 1.7 and 3.7 days per month, respectively, by the end of the first year. Hospital/medical care days per month of life were higher in patients with shorter survival but increased sharply at the end of life in all patients, regardless of duration of survival. In patients with locoregional disease, resection was associated with a higher number of hospital/medical care days during the first 4 months after diagnosis, but fewer at the end of the first year. For distant disease, hospital days were similar but days in medical care were higher for patients receiving chemotherapy, increasing especially at the end of life. Conclusions: This study is the first to quantify hospital/medical care days in patients with pancreatic cancer by stage, treatment, and survival. This information will provide realistic expectations and allow for treatment decisions based on patient preferences.

Original languageEnglish (US)
Pages (from-to)2435-2442
Number of pages8
JournalAnnals of Surgical Oncology
Volume19
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Medical Day Care
Pancreatic Neoplasms
Survival
Patient Preference
Therapeutics
Medicare
Epidemiology
Drug Therapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Boyd, C. A., Branch, D. W., Sheffield, K. M., Han, Y., Kuo, Y. F., Goodwin, J., & Riall, T. S. (2012). Hospital and medical care days in pancreatic cancer. Annals of Surgical Oncology, 19(8), 2435-2442. https://doi.org/10.1245/s10434-012-2326-2

Hospital and medical care days in pancreatic cancer. / Boyd, Casey A.; Branch, Daniel W.; Sheffield, Kristin M.; Han, Yimei; Kuo, Yong Fang; Goodwin, James; Riall, Taylor S.

In: Annals of Surgical Oncology, Vol. 19, No. 8, 08.2012, p. 2435-2442.

Research output: Contribution to journalArticle

Boyd, CA, Branch, DW, Sheffield, KM, Han, Y, Kuo, YF, Goodwin, J & Riall, TS 2012, 'Hospital and medical care days in pancreatic cancer', Annals of Surgical Oncology, vol. 19, no. 8, pp. 2435-2442. https://doi.org/10.1245/s10434-012-2326-2
Boyd, Casey A. ; Branch, Daniel W. ; Sheffield, Kristin M. ; Han, Yimei ; Kuo, Yong Fang ; Goodwin, James ; Riall, Taylor S. / Hospital and medical care days in pancreatic cancer. In: Annals of Surgical Oncology. 2012 ; Vol. 19, No. 8. pp. 2435-2442.
@article{5d5541b3bba0452cbaeee477d15a581c,
title = "Hospital and medical care days in pancreatic cancer",
abstract = "Background: Little is known about resource utilization (number of days in the hospital or medical care) between diagnosis and death in patients with pancreatic cancer. Methods: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified 25,476 patients with pancreatic cancer (1992-2005). Hospital and medical care days per person-month from the time of diagnosis were described, stratified by stage, treatment, and survival duration. Results: Hospital/medical care days vary by length of survival and treatment strategy in patients with pancreatic cancer. For all stages, patients were in the hospital a mean of 6.4 days and received medical care a total of 9.0 days in the first month after diagnosis, decreasing to 1.7 and 3.7 days per month, respectively, by the end of the first year. Hospital/medical care days per month of life were higher in patients with shorter survival but increased sharply at the end of life in all patients, regardless of duration of survival. In patients with locoregional disease, resection was associated with a higher number of hospital/medical care days during the first 4 months after diagnosis, but fewer at the end of the first year. For distant disease, hospital days were similar but days in medical care were higher for patients receiving chemotherapy, increasing especially at the end of life. Conclusions: This study is the first to quantify hospital/medical care days in patients with pancreatic cancer by stage, treatment, and survival. This information will provide realistic expectations and allow for treatment decisions based on patient preferences.",
author = "Boyd, {Casey A.} and Branch, {Daniel W.} and Sheffield, {Kristin M.} and Yimei Han and Kuo, {Yong Fang} and James Goodwin and Riall, {Taylor S.}",
year = "2012",
month = "8",
doi = "10.1245/s10434-012-2326-2",
language = "English (US)",
volume = "19",
pages = "2435--2442",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Hospital and medical care days in pancreatic cancer

AU - Boyd, Casey A.

AU - Branch, Daniel W.

AU - Sheffield, Kristin M.

AU - Han, Yimei

AU - Kuo, Yong Fang

AU - Goodwin, James

AU - Riall, Taylor S.

PY - 2012/8

Y1 - 2012/8

N2 - Background: Little is known about resource utilization (number of days in the hospital or medical care) between diagnosis and death in patients with pancreatic cancer. Methods: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified 25,476 patients with pancreatic cancer (1992-2005). Hospital and medical care days per person-month from the time of diagnosis were described, stratified by stage, treatment, and survival duration. Results: Hospital/medical care days vary by length of survival and treatment strategy in patients with pancreatic cancer. For all stages, patients were in the hospital a mean of 6.4 days and received medical care a total of 9.0 days in the first month after diagnosis, decreasing to 1.7 and 3.7 days per month, respectively, by the end of the first year. Hospital/medical care days per month of life were higher in patients with shorter survival but increased sharply at the end of life in all patients, regardless of duration of survival. In patients with locoregional disease, resection was associated with a higher number of hospital/medical care days during the first 4 months after diagnosis, but fewer at the end of the first year. For distant disease, hospital days were similar but days in medical care were higher for patients receiving chemotherapy, increasing especially at the end of life. Conclusions: This study is the first to quantify hospital/medical care days in patients with pancreatic cancer by stage, treatment, and survival. This information will provide realistic expectations and allow for treatment decisions based on patient preferences.

AB - Background: Little is known about resource utilization (number of days in the hospital or medical care) between diagnosis and death in patients with pancreatic cancer. Methods: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified 25,476 patients with pancreatic cancer (1992-2005). Hospital and medical care days per person-month from the time of diagnosis were described, stratified by stage, treatment, and survival duration. Results: Hospital/medical care days vary by length of survival and treatment strategy in patients with pancreatic cancer. For all stages, patients were in the hospital a mean of 6.4 days and received medical care a total of 9.0 days in the first month after diagnosis, decreasing to 1.7 and 3.7 days per month, respectively, by the end of the first year. Hospital/medical care days per month of life were higher in patients with shorter survival but increased sharply at the end of life in all patients, regardless of duration of survival. In patients with locoregional disease, resection was associated with a higher number of hospital/medical care days during the first 4 months after diagnosis, but fewer at the end of the first year. For distant disease, hospital days were similar but days in medical care were higher for patients receiving chemotherapy, increasing especially at the end of life. Conclusions: This study is the first to quantify hospital/medical care days in patients with pancreatic cancer by stage, treatment, and survival. This information will provide realistic expectations and allow for treatment decisions based on patient preferences.

UR - http://www.scopus.com/inward/record.url?scp=84864987972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864987972&partnerID=8YFLogxK

U2 - 10.1245/s10434-012-2326-2

DO - 10.1245/s10434-012-2326-2

M3 - Article

VL - 19

SP - 2435

EP - 2442

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -